Table S1.
Patient characteristics by treatment settings
| Characteristics | Set A, no (%) | Set B, no (%) |
|---|---|---|
| Her-2 status | ||
| Positive | 42 (100.0) | 0 |
| Negative | 0 | 68 (100.0) |
| Age (years) | ||
| Median (range) | 56 (25–72) | 51 (22–73) |
| Gender | ||
| Male | 32 (76.2) | 34 (50.0) |
| Female | 10 (23.8) | 34 (50.0) |
| Gastrectomy | ||
| Yes | 33 (78.6) | 50 (73.5) |
| No | 9 (21.4) | 18 (26.5) |
| Location of tumor | ||
| Proximal | 12 (28.6) | 11 (16.2) |
| Middle | 15 (35.7) | 17 (25.0) |
| Distal | 14 (33.3) | 35 (51.5) |
| Others | 1 (2.4) | 5 (7.4) |
| Degree of differentiation | ||
| Well-differentiated adenocarcinoma | 2 (4.8) | 1 (1.5) |
| Moderate differentiated adenocarcinoma | 13 (31.0) | 7 (10.3) |
| Poorly differentiated/signet ring cell carcinoma/mucinous adenocarcinoma | 27 (64.3) | 60 (88.2) |
| Lauren classification | ||
| Intestinal type | 14 (33.3) | 2 (2.9) |
| Diffuse type | 23 (54.8) | 45 (66.2) |
| Mixed type | 5 (11.9) | 21 (30.9) |
Notes: Setting A: patients with Her-2-positive GC who received trastuzumab combined with chemotherapy as the first-line treatment. Setting B: patients with Her-2-negative GC who received chemotherapy only as the first-line treatment.
Abbreviation: GC, gastric cancer.